other:
Control:Article Title: Evaluation of measurement uncertainty of coagulation parameters according to two different current guidelines
Article Snippet: How to cite this article: Zeytinli Aksit M. Evaluation of measurement uncertainty of coagulation parameters according to two different current guidelines.. Int J Med Biochem 2025;8(1):27–31.. DOI: Research Article Int J Med Biochem 2025;8(1):27–31 10.14744/ijmb.2024.90377 Int J Med Biochem 28 and bias (uBias) should be included in the calculation only when a significant medical difference is observed [4].
Article Title:
Article Snippet: .. 5.0 Statement of Intended Use Lyphochek@ Coagulation Control is intended for use as a quality control plasma to monitor the precision of citrated coagulation systems Bio-Rad Laboratories Premarket Notification Section 510(k) for LyphochekQ Coagulation Control Summary of Safety and Effectiveness Page 2 of 2 Formulation Does not contain constituents of animal origin 6.0 Comparison of the new device with the Predicate Device The new Lyphochek@ Coagulation Control Level 4 claims substantial equivalence to the Lyphochek@ Coagulation Control currently in commercial distribution (KO1 2722). ..
Article Title:
Article Snippet: .. SEP 17 2003 Bio-Rad Laboratories Premarket Notification Section 510(k) for LyphochekQ Coagulation Control Level 4 Summarv of Safetv and Effectiveness Page 1 of 2 Summary of Safety and Effectiveness Lyphochek@ Coagulation Control Level 4 1.0 Submitter Bio-Rad Laboratories 9500 Jeronimo Road, Irvine, California 92618-2017 Telephone: (949) 598-1 200 Contact Person Maria Zeballos Regulatory Affairs Specialist Telephone: (949) 598-1 367 Fax: (949) 598-1 555 Date of Summary Preparation August 11,2003 2.0 Device Identification Product Trade Name: Common Name: Plasma Coagulation Control Lyphochek@ Coagulation Control Level 4 Classifications: Class II Product Code: GGN Regulation Number: 21 CFR 864.5425 Device to Which Substantial Eauivalence is Claimed Lyphochek@ Coagulation Control Bio-Rad Laboratories Irvine, California Docket Number: KO1 2722 - 3.0 4.0 Description of Device Lyphochek@ Coagulation Control is prepared from human plasma, with added purified biochemicals (tissue extract from animal origin), and preservatives. ..
Coagulation:Article Title: Evaluation of measurement uncertainty of coagulation parameters according to two different current guidelines
Article Snippet: How to cite this article: Zeytinli Aksit M. Evaluation of measurement uncertainty of coagulation parameters according to two different current guidelines.. Int J Med Biochem 2025;8(1):27–31.. DOI: Research Article Int J Med Biochem 2025;8(1):27–31 10.14744/ijmb.2024.90377 Int J Med Biochem 28 and bias (uBias) should be included in the calculation only when a significant medical difference is observed [4].
Article Title:
Article Snippet: .. 5.0 Statement of Intended Use Lyphochek@ Coagulation Control is intended for use as a quality control plasma to monitor the precision of citrated coagulation systems Bio-Rad Laboratories Premarket Notification Section 510(k) for LyphochekQ Coagulation Control Summary of Safety and Effectiveness Page 2 of 2 Formulation Does not contain constituents of animal origin 6.0 Comparison of the new device with the Predicate Device The new Lyphochek@ Coagulation Control Level 4 claims substantial equivalence to the Lyphochek@ Coagulation Control currently in commercial distribution (KO1 2722). ..
Article Title:
Article Snippet: .. SEP 17 2003 Bio-Rad Laboratories Premarket Notification Section 510(k) for LyphochekQ Coagulation Control Level 4 Summarv of Safetv and Effectiveness Page 1 of 2 Summary of Safety and Effectiveness Lyphochek@ Coagulation Control Level 4 1.0 Submitter Bio-Rad Laboratories 9500 Jeronimo Road, Irvine, California 92618-2017 Telephone: (949) 598-1 200 Contact Person Maria Zeballos Regulatory Affairs Specialist Telephone: (949) 598-1 367 Fax: (949) 598-1 555 Date of Summary Preparation August 11,2003 2.0 Device Identification Product Trade Name: Common Name: Plasma Coagulation Control Lyphochek@ Coagulation Control Level 4 Classifications: Class II Product Code: GGN Regulation Number: 21 CFR 864.5425 Device to Which Substantial Eauivalence is Claimed Lyphochek@ Coagulation Control Bio-Rad Laboratories Irvine, California Docket Number: KO1 2722 - 3.0 4.0 Description of Device Lyphochek@ Coagulation Control is prepared from human plasma, with added purified biochemicals (tissue extract from animal origin), and preservatives. ..
Clinical Proteomics:Article Title:
Article Snippet: .. 5.0 Statement of Intended Use Lyphochek@ Coagulation Control is intended for use as a quality control plasma to monitor the precision of citrated coagulation systems Bio-Rad Laboratories Premarket Notification Section 510(k) for LyphochekQ Coagulation Control Summary of Safety and Effectiveness Page 2 of 2 Formulation Does not contain constituents of animal origin 6.0 Comparison of the new device with the Predicate Device The new Lyphochek@ Coagulation Control Level 4 claims substantial equivalence to the Lyphochek@ Coagulation Control currently in commercial distribution (KO1 2722). ..
Article Title:
Article Snippet: .. SEP 17 2003 Bio-Rad Laboratories Premarket Notification Section 510(k) for LyphochekQ Coagulation Control Level 4 Summarv of Safetv and Effectiveness Page 1 of 2 Summary of Safety and Effectiveness Lyphochek@ Coagulation Control Level 4 1.0 Submitter Bio-Rad Laboratories 9500 Jeronimo Road, Irvine, California 92618-2017 Telephone: (949) 598-1 200 Contact Person Maria Zeballos Regulatory Affairs Specialist Telephone: (949) 598-1 367 Fax: (949) 598-1 555 Date of Summary Preparation August 11,2003 2.0 Device Identification Product Trade Name: Common Name: Plasma Coagulation Control Lyphochek@ Coagulation Control Level 4 Classifications: Class II Product Code: GGN Regulation Number: 21 CFR 864.5425 Device to Which Substantial Eauivalence is Claimed Lyphochek@ Coagulation Control Bio-Rad Laboratories Irvine, California Docket Number: KO1 2722 - 3.0 4.0 Description of Device Lyphochek@ Coagulation Control is prepared from human plasma, with added purified biochemicals (tissue extract from animal origin), and preservatives. ..
Formulation:Article Title:
Article Snippet: .. 5.0 Statement of Intended Use Lyphochek@ Coagulation Control is intended for use as a quality control plasma to monitor the precision of citrated coagulation systems Bio-Rad Laboratories Premarket Notification Section 510(k) for LyphochekQ Coagulation Control Summary of Safety and Effectiveness Page 2 of 2 Formulation Does not contain constituents of animal origin 6.0 Comparison of the new device with the Predicate Device The new Lyphochek@ Coagulation Control Level 4 claims substantial equivalence to the Lyphochek@ Coagulation Control currently in commercial distribution (KO1 2722). ..
Comparison:Article Title:
Article Snippet: .. 5.0 Statement of Intended Use Lyphochek@ Coagulation Control is intended for use as a quality control plasma to monitor the precision of citrated coagulation systems Bio-Rad Laboratories Premarket Notification Section 510(k) for LyphochekQ Coagulation Control Summary of Safety and Effectiveness Page 2 of 2 Formulation Does not contain constituents of animal origin 6.0 Comparison of the new device with the Predicate Device The new Lyphochek@ Coagulation Control Level 4 claims substantial equivalence to the Lyphochek@ Coagulation Control currently in commercial distribution (KO1 2722). ..
Purification:Article Title:
Article Snippet: .. SEP 17 2003 Bio-Rad Laboratories Premarket Notification Section 510(k) for LyphochekQ Coagulation Control Level 4 Summarv of Safetv and Effectiveness Page 1 of 2 Summary of Safety and Effectiveness Lyphochek@ Coagulation Control Level 4 1.0 Submitter Bio-Rad Laboratories 9500 Jeronimo Road, Irvine, California 92618-2017 Telephone: (949) 598-1 200 Contact Person Maria Zeballos Regulatory Affairs Specialist Telephone: (949) 598-1 367 Fax: (949) 598-1 555 Date of Summary Preparation August 11,2003 2.0 Device Identification Product Trade Name: Common Name: Plasma Coagulation Control Lyphochek@ Coagulation Control Level 4 Classifications: Class II Product Code: GGN Regulation Number: 21 CFR 864.5425 Device to Which Substantial Eauivalence is Claimed Lyphochek@ Coagulation Control Bio-Rad Laboratories Irvine, California Docket Number: KO1 2722 - 3.0 4.0 Description of Device Lyphochek@ Coagulation Control is prepared from human plasma, with added purified biochemicals (tissue extract from animal origin), and preservatives. ..
|
Bio-Rad is a verified supplier 
Bio-Rad manufactures this product 